Top

International Journal of Colorectal Disease

Published in:

01-12-2012 | Original Article

Expression of vascular endothelial growth factor can predict distant metastasis and disease-free survival for clinical stage III rectal cancer following 30-Gy/10-f preoperative radiotherapy

Authors: Yifan Peng, Lin Wang, Changzheng Du, Jin Gu

Published in: International Journal of Colorectal Disease | Issue 12/2012

Abstract

Purpose

The purpose of this study was to analyze the prognostic value of vascular endothelial growth factor (VEGF) in patients with stage III rectal cancer treated with 30-Gy/10-fraction (f) preoperative radiotherapy and radical surgery.

Methods

One hundred and sixteen patients with clinical stage III rectal cancer were studied. All patients underwent radical surgery after 30-Gy/10-f preoperative radiotherapy. Immunohistochemical examination of VEGF was performed on the resected tumor specimen. An immunohistochemical score established from the extension and intensity of the markers was used for analysis. The log-rank test and proportional hazards regression analysis were used to calculate the probability that this biomarker was associated with patient outcomes.

Results

The expression of VEGF was identified among 74.1 % (86 of 116) of patients. We found an increased incidence of distant metastasis (19.8 vs. 3.3 %, p = 0.039) and a decreased 3-year disease-free survival rate (96.7 % vs. 72.7 %, p = 0.003) in patients with positive VEGF staining. In multivariate survival analysis, positive VEGF staining (hazard ratio (HR) = 9.364, 95 % confidence interval (CI) 1.298–71.519, p = 0.027) and ypN+ stage (HR = 2.714, 95 % CI 1.419–3.331, p = 0.000) were the independent prognostic factors for disease-free survival. Subgroup analyses showed that the expression of VEGF was significantly associated with increased distant metastasis rate and decreased DFS in patients with ypN+ stage.

Conclusions

VEGF expression may have potential value for predicting distant metastasis and disease-free survival in stage III rectal cancer after 30-Gy/10-f preoperative radiotherapy. Inhibition of VEGF in combination with radiotherapy may improve the patient outcomes.

Jemal A et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225–249PubMedCrossRef

Li M, Gu J (2005) Changing patterns of colorectal cancer in China over a period of 20 years. World J Gastroenterol 11(30):4685–4688PubMed

Glynne-Jones R et al (2007) The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of rectal cancer. Best Pract Res Clin Gastroenterol 21(6):1049–1070PubMedCrossRef

Sebag-Montefiore D, Bujko K, Valentini V (2009) Rectal cancer multidisciplinary management: evidences and future landscape. Radiother Oncol 92(2):145–147PubMedCrossRef

Bisceglia G et al (2010) Effectiveness of neoadjuvant radiotherapy in the treatment of locally advanced rectal cancer: a single-center experience in 263 patients. Dig Surg 27(3):217–223PubMedCrossRef

Valentini V et al (2009) Multidisciplinary rectal cancer management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol 92(2):148–163PubMedCrossRef

Peeters KC et al (2007) The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246(5):693–701PubMedCrossRef

Bosset JF et al (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355(11):1114–1123PubMedCrossRef

Sauer R et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351(17):1731–1740PubMedCrossRef

10.

Sebag-Montefiore D et al (2009) Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 373(9666):811–820PubMedCrossRef

11.

Folkman J (1992) The role of angiogenesis in tumor growth. Semin Cancer Biol 3(2):65–71PubMed

12.

Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669–676PubMedCrossRef

13.

Campa D et al (2010) A gene-wide investigation on polymorphisms in the taste receptor 2R14 (TAS2R14) and susceptibility to colorectal cancer. BMC Med Genet 11:88PubMedCrossRef

14.

Camma C et al (2000) Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA 284(8):1008–1015PubMedCrossRef

15.

Heald RJ, Ryall RD (1986) Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1(8496):1479–1482PubMedCrossRef

16.

Saito H et al (1998) Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br J Cancer 78(12):1573–1577PubMedCrossRef

17.

Nieder C et al (2007) Radiation therapy plus angiogenesis inhibition with bevacizumab: rationale and initial experience. Rev Recent Clin Trials 2(3):163–168PubMedCrossRef

18.

Galizia G et al (2004) Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res 10(10):3490–3499PubMedCrossRef

19.

Roskoski R Jr (2007) Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 62(3):179–213PubMedCrossRef

20.

Gupta VK et al (2002) Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 8(1):47–54PubMedCrossRef

21.

Gorski DH et al (1999) Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59(14):3374–3378PubMed

22.

Giatromanolaki A, Sivridis E, Koukourakis MI (2006) Angiogenesis in colorectal cancer: prognostic and therapeutic implications. Am J Clin Oncol 29(4):408–417PubMedCrossRef

23.

Giralt J et al (2006) Prognostic significance of vascular endothelial growth factor and cyclooxygenase-2 in patients with rectal cancer treated with preoperative radiotherapy. Oncology 71(5–6):312–319PubMedCrossRef

24.

Nozue M, Isaka N, Fukao K (2001) Over-expression of vascular endothelial growth factor after preoperative radiation therapy for rectal cancer. Oncol Rep 8(6):1247–1249PubMed

25.

Yancopoulos GD et al (2000) Vascular-specific growth factors and blood vessel formation. Nature 407(6801):242–248PubMedCrossRef

26.

Winkler F et al (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6(6):553–563PubMed

27.

Li J et al (2005) Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade. Int J Radiat Oncol Biol Phys 62(5):1477–1485PubMedCrossRef

28.

Kozin SV et al (2001) Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 61(1):39–44PubMed

29.

Lee CG et al (2000) Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60(19):5565–5570PubMed

Title: Expression of vascular endothelial growth factor can predict distant metastasis and disease-free survival for clinical stage III rectal cancer following 30-Gy/10-f preoperative radiotherapy
Authors: Yifan Peng
Lin Wang
Changzheng Du
Jin Gu
Publication date: 01-12-2012
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 12/2012
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-012-1485-8

At a glance: The STEP trials

Springer Medicine

Expression of vascular endothelial growth factor can predict distant metastasis and disease-free survival for clinical stage III rectal cancer following 30-Gy/10-f preoperative radiotherapy

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2012

Influence of size and complexity of the hospitals in an enhanced recovery programme for colorectal resection

Infliximab for the prevention of postoperative recurrence in patients with multiple surgeries for Crohn’s disease

Letter to the editor: a meta-analysis of MMP-2 expression on the survival of patients with colorectal cancer

Neuroprotective effect of neurotropin on chronic oxaliplatin-induced neurotoxicity in stage II and stage III colorectal cancer patients: results from a prospective, randomised, single-centre, pilot clinical trial

Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer

Manuscript ‘close shave’ margins do not increase rectal cancer recurrence after sphincter-saving surgery without neoadjuvant therapy by Lim et al.